Amir Rehman
Psychiatry · Alexandria, VANPI 1801983176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 28.2% of the total. Reporting peaked in 2022 at $2,290 and has fallen 76.0% since, to $551 in 2025. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $29.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Supernus Pharmaceuticals, Inc.$1K
- Sunovion Pharmaceuticals Inc.$991
- Johnson & Johnson$883
- Otsuka America Pharmaceutical, Inc.$736
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$582
- plus $3K from 20 others
What the payments were for
- Food & beverage$9,51999%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $2,702 |
| Supernus Pharmaceuticals, Inc. | 38 | $1,074 |
| Sunovion Pharmaceuticals Inc. | 45 | $991 |
| Johnson & Johnson | 16 | $883 |
| Otsuka America Pharmaceutical, Inc. | 25 | $736 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $582 |
| Axsome Therapeutics, Inc. | 17 | $539 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $461 |
| Alkermes, Inc. | 11 | $337 |
| Lundbeck LLC | 12 | $298 |
| Ironshore Pharmaceuticals Inc. | 4 | $215 |
| Idorsia Pharmaceuticals US Inc | 4 | $192 |
| Neurocrine Biosciences, Inc. | 2 | $104 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Corium, LLC | 3 | $64 |
| Shire North American Group Inc | 4 | $55 |
| Orexo US, Inc. | 3 | $54 |
| Eisai Inc. | 3 | $52 |
| Neos Therapeutics, LP | 2 | $33 |
| Bard Peripheral Vascular, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $33 |
| Tris Pharma Inc | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,594 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $3,321 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 69 | $1,570 |
| Armodafinil | 12 | $1,192 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $1,008 |
| Methylphenidate Hcl | 20 | $475 |
| Eszopiclone | 29 | $407 |
| Duloxetine Hcl | 19 | $270 |
| Alprazolam | 41 | $244 |
| Paroxetine Hcl | 15 | $176 |
| Zolpidem Tartrate | 24 | $93 |
| Topiramate | 11 | $71 |
| Trazodone Hcl | 14 | $70 |
| Lorazepam | 19 | $64 |
| Sertraline Hcl | 20 | $51 |
| Clonazepam | 37 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orexo US, Inc.Zubsolv | $54 | $3,32113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Alexandria
- Anne DietrichAlexandria$13K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
- Timothy KaneStaunton$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.